Drug Initiative

Is the FDA ignoring heart risks from high triglycerides in the face of mounting evidence to the contrary?

The lives of millions of Americans are potentially at risk.

The EPA Drug Initiative (EPADI) urges the FDA to thoughtfully consider new and almost irrefutable proof that high triglycerides are a significant risk factor contributing to cardiovascular disease-related death and morbidity.

Recently, two independent studies were published in the prestigious New England Journal of Medicine (NEJM), both drawing the same conclusion: that reducing serum triglycerides to accepted, safe levels resulted in a 40% decrease in cardiovascular risk. These trial results are being universally hailed as groundbreaking, as they focus on people having a certain gene mutation, which elegantly eliminates all cardiovascular disease risk factors other than serum triglyceride levels. Both studies—from well-respected researchers—have caught the attention of the world, with the results being published by prominent news media including the New York Times and Forbes.

Read the Full Story

I just wanted to share how amazing my results have been after taking Vascepa for about 4 1/2 months. I am 63 and a Type I diabetic, based on an autoimmune response at age 49. I take small doses of insulin -- both Humalog and Lantus, but have trouble with tight control because of my concern about low blood sugars. Lots of good things have been happening since my MD prescribed the Vascepa. A1C came down a whole percentage point -- Amazing since it hadn't budged in 4 years and I have not changed other regimes. HDL got 10 points higher, LDL no higher. and triglycerides are lower. Plus -- I feel more energetic, eyes are moister and healthier, allergies less severe, and skin more supple. I am thrilled with these results!

Anna Carroll
Austin, TX
Back To Top